Compounded tirzepatide quality claims: what the evidence shows

What did @therealdrleemd actually say?

Dr. Lee claims that after tirzepatide was removed from the FDA shortage list, some compounding companies may have started using "less tirzepatide" in their formulations to increase profit margins. He suggests patients whose medication feels "weaker" should investigate their compounding pharmacy on Reddit, and positions his own service as more trustworthy. That's the core of it.

He stops just short of making a direct accusation, using hedging language like "I'm not saying that's what's happening to you." But the framing is clear: if your medication feels weaker, a shady compounder is probably cutting corners. He then pivots to a soft pitch for his own platform. That combination, vague fear plus a brand plug, deserves scrutiny.

Does the science back this up?

The concern about compounded GLP-1 quality is real and documented, but the specific mechanism Dr. Lee describes is only part of the story. The FDA removed tirzepatide from its drug shortage list in December 2024, which legally required most compounding pharmacies to stop producing copies. The agency had already flagged quality concerns.

The FDA issued a safety alert in 2024 noting reports of adverse events tied to compounded semaglutide and tirzepatide, including dosing errors and products of uncertain potency. A 2023 analysis by Downing et al. in JAMA Internal Medicine raised broader concerns about the variability in compounded drug quality, though it did not focus specifically on GLP-1 peptides. Independent lab testing by outlets including Bloomberg and various consumer watchdog groups found that some compounded tirzepatide products had potency levels that varied significantly from labeled claims. So yes, the quality concern is real. But attributing it primarily to deliberate profit-motivated dilution is speculative.

What did they get wrong (or right)?

He got the broad concern right. Compounded tirzepatide quality is genuinely variable, and patients have reported efficacy differences between products. That is not invented.

What he got wrong, or at least oversimplified, is the cause. He implies the main risk is deliberate under-dosing for profit. In reality, compounding pharmacies face significant technical challenges in producing stable peptide formulations at consistent potency. Degradation during storage, improper pH buffering, and lack of standardized testing protocols are more commonly documented issues than intentional dilution. The FDA's own 503A and 503B compounding oversight frameworks identify process failures as the primary concern, not fraud.

He also recommends Reddit as a research tool for evaluating your pharmacy. Reddit threads are anecdote aggregators. They are not a substitute for verifying a pharmacy's accreditation through PCAB or checking FDA warning letter databases. That recommendation is genuinely poor advice dressed up as insider knowledge.

Finally, calling his own service ethical without disclosing any specifics about his pharmacy sourcing or testing protocols is exactly the kind of vague reassurance patients should push back on.

What should you actually know?

If you are using compounded tirzepatide and notice reduced efficacy, there are legitimate reasons that have nothing to do with a shady compounder cheating you. Formulation changes after the shortage list removal are real. Some pharmacies shifted to tirzepatide with added ingredients like B12 or niacinamide, which may affect how the product behaves. Improper storage on the patient side is also a common and underappreciated factor with peptide-based medications.

If you want to actually evaluate a compounding pharmacy, check whether they hold PCAB accreditation, whether they operate under 503B outsourcing facility standards, and whether they provide certificates of analysis from third-party testing. Those are verifiable credentials. A Reddit thread is not. Ask your prescriber directly what testing standards their pharmacy partner uses. If they cannot answer that question, that tells you something meaningful.

• PCAB accreditation is a voluntary but meaningful quality benchmark for compounding pharmacies.
• 503B outsourcing facilities are subject to FDA inspection and current good manufacturing practices, unlike standard 503A pharmacies.
• The FDA maintains a public database of warning letters and 483 inspection observations you can actually search.
• Certificates of analysis from independent labs are the closest thing to objective potency verification a patient can access.